Uttarakhand takes steps for environmentally responsible disposal of medicines
Chief Minister Pushkar Singh Dhami has started work towards implementing the guidelines issued by the Central Drugs Standard Control Organisation (CDSCO), Ministry of Health and Family Welfare in the state.
This decision is not just an administrative process, but a transformative initiative towards making Uttarakhand a model state of "
green health system
" across the country, a release said.
Health Secretary and Commissioner of the FDA, Dr. R. Rajesh Kumar, said that till now, there has been a lack of a clear and consistent system for the disposal of expired and unused medicines.
"This challenge becomes more serious in an environmentally sensitive state like Uttarakhand. Now we are moving towards controlling it under a well-planned system," Kumar said.
He informed that in these guidelines, the process has been decided keeping in mind every stage of the life cycle of medicines from production to consumption and then proper disposal.
Kumar further said that under the "Healthy Citizen, Clean Uttarakhand" mission announced by the Chief Minister, this initiative will take the state towards a green and sustainable healthcare model.
With this decision, the possibility of establishing the state as a leading state in the field of environmental responsibility and health security at the national and international level has also become stronger.
Only the active participation of all the parties involved in this entire process, policy makers, business organizations and common citizens can make this mission successful. Uttarakhand is moving towards becoming an example in this direction.
Dr. R. Rajesh Kumar informed that as per the plan of the Health Department, "
Drug Take-Back Sites
" will be set up in a phased manner in urban, semi-urban and hilly areas of Uttarakhand.
Here common citizens will be able to deposit unused, expired or spoiled medicines lying in their homes. Medicines from these centers will be collected scientifically and disposed of in specially approved processing units.
Dr. R. Rajesh Kumar said that the CDSCO guideline presents a scientific framework for safe disposal of medicines. It has a provision to divide medicines into categories like expired, unused, recalled and spoiled in cold chain. Techniques like incineration and encapsulation have been suggested for disposal.
Arrangements like color-coded biomedical waste bags, tracking and log book system make it more effective. This guideline has been prepared in accordance with WHO standards and Biomedical Waste Management Rules 2016, so that the side effects of medicines on human health and environment can be reduced.
Additional Commissioner FDA and Drug Controller Tajbar Singh Jaggi said that the system that was in place till now regarding the disposal of medicines in the state was scattered and unorganized.
"Now we will control it through a 'third party monitoring system' and local drug enforcement units. Accountability will be fixed for all the manufacturing companies, wholesalers and retailers, hospitals and consumers. We will also run extensive public awareness campaigns in this direction so that common citizens also become partners in this system," Jaggi said.
He further added that this step is necessary because uncontrolled disposal of medicines can pose a serious threat not only to the environment but also to public health. Such disposal can lead to mixing of toxic chemicals in rivers, lakes and underground water sources, which harms natural resources. At the same time, if the medicines come in contact with animals or children, a serious health crisis can arise.
Apart from this, global problems like antimicrobial resistance (AMR) can also increase due to wrong and excessive use of medicines. The Uttarakhand government has made solid preparations to deal with these challenges.
The Additional Commissioner and Drug Controller said that the State Drug Control Department would be made the monitoring agency, the Druggists and Chemists Association would be linked to the take-back system, task forces would be formed in the districts and arrangements would be made for monitoring and audit of data through the e-drug log system.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
10 hours ago
- Time of India
‘Child scratched by stray turned away by hosp due to lack of rabies vaccine'
New Delhi: Barely three days after the Supreme Court directed authorities to ensure immediate treatment for dog-bite victims and maintain adequate anti-rabies vaccine (ARV) stocks, a 22-month-old girl scratched on both thighs by a stray dog was allegedly turned away from the Delhi govt-run Dr Hedgewar Aarogya Sansthan on Thursday night due to unavailability of the vaccine. The child's father, Munna Kumar, a resident of Radhey Shyam Park in Krishna Nagar, told TOI that earlier in the day, his daughter was playing outside her relative's home in Noida, near Sector 78, when a stray dog attacked her. "She was scratched on both legs. We rushed to Hedgewar Hospital in Karkardooma around 9pm, but the doctors said they didn't have the vaccine and asked us to go to another hospital," he alleged. You Can Also Check: Delhi AQI | Weather in Delhi | Bank Holidays in Delhi | Public Holidays in Delhi | Gold Rates Today in Delhi | Silver Rates Today in Delhi According to the outpatient casualty card, which was reviewed by TOI, the attending doctor recorded the case as "dog bite" Category II — which, under WHO guidelines, includes nibbling of uncovered skin, minor scratches or abrasions without bleeding. The note further read: "Injection ARV N/A and refer to any govt hospital for ARV inj." Kumar said they then rushed to Delhi govt-run Guru Teg Bahadur (GTB) Hospital, where staff told them to return in the morning. "It was already late at night, and we were worried about delaying the treatment, but they said the vaccine would be given only the next day," he said. The child was finally administered the first dose of ARV at GTB Hospital on Friday morning — nearly half a day after the attack — and her father was asked to return on Aug 18 for the second dose. According to a senior official of Hedgewar Hospital, "The demand was raised almost three months ago with the central procurement agency, and we are still waiting for the supply. We are expecting it next week." When contacted, a senior GTB Hospital official said they were unaware of the matter but would look into why the vaccine was not administered at night, adding that anti-rabies vaccines are available round-the-clock. In its Aug 11 order, SC had emphasised that civic agencies must capture and house stray dogs in shelters within 6-8 weeks, sterilise and vaccinate them, and — most crucially — ensure bite victims receive "immediate treatment". The court also directed that vaccine availability data be made public and helplines be created for bite cases. Thursday's incident highlights the gap between the apex court's directives and ground realities. The lack of ARV at Hedgewar Hospital, forcing the child's family to travel to another facility to get the lifesaving injection, underscores the urgent need for real-time stock monitoring across all hospitals. Stay updated with the latest local news from your city on Times of India (TOI). Check upcoming bank holidays , public holidays , and current gold rates and silver prices in your area. Get the latest lifestyle updates on Times of India, along with Happy Krishna Janmashtami Wishes ,, messages , and quotes !
Hindustan Times
a day ago
- Hindustan Times
FDA launches festive campaign to ensure food standards in the state
Mumbai: The Maharashtra Food and Drug Administration (FDA) on Monday launched a special campaign titled 'San Maharashtracha, Sankalp Anna Surakshathika Abhiyan,' to ensure hygiene and safety standards in the food sold during the upcoming festive seasons of Ganeshotsav, Eid, Navratri, Dussehra and Diwali in the state from August 11 to October 25. The campaign includes sudden inspections of eateries to keep in check food adulteration and ensure compliance with hygiene standards. The authority is also set to organise workshops to spread awareness about the standards to be met. FDA launches festive campaign to ensure food standards in the state The initiative was launched on Monday by the FDA secretary Dheeraj Kumar, along with FDA commissioner Rajesh Narvekar and senior department officials at the Yashwantrao Chavan Centre, followed by a training session for food professionals, aiming at educating traders on hygiene practices and legal compliance during the high-demand festive period. 'During festivals, the demand for sweets, modaks, faral and prasad skyrockets. This is when the risk of adulteration increases, as some traders may cut corners due to supply shortages,' FDA secretary Dheeraj Kumar said. Food businesses should strictly follow food safety standards, avoid malpractices, and ensure products are wholesome and hygienic, he added. 'We are increasing the number of food testing labs in the state. We are also working on providing manpower for the department.' FDA commissioner Rajesh Narvekar said, 'Adulteration is often detected when market demand exceeds supply. Through our training, we hope traders will comply fully with the law so that festivals can be celebrated without compromising health.' As part of the campaign, workshops on food hygiene will be conducted for those handling mandals, sweet manufacturers, and women's self-help groups that prepare festive foods. The authority will also carry out surprise inspections of food outlets, sweet shops, street vendors and production units across the state, including Mumbai, Pune, Nagpur and Chhatrapati Sambhajinagar.
Time of India
2 days ago
- Time of India
Is Novo Nordisk facing its 'Nokia moment'? Stock tumbles to $50 from a year-high of $139 amid disruptive rivals and shifting market forces
Novo Nordisk's stock has tumbled from record highs after slashing its 2025 outlook, as fierce competition, leadership changes, and legal challenges fuel concerns over the Danish drugmaker's grip on the global diabetes and obesity market. Novo Nordisk, Denmark's pharma powerhouse, has seen its stock plunge from record highs as fierce competition, slowing growth, and market shifts test its dominance in the global diabetes and obesity drug market. Tired of too many ads? Remove Ads Intensifying Competitive Pressures Compounded versions from U.S. pharmacies —driven by FDA shortages—have eaten into branded sales. —driven by FDA shortages—have eaten into branded sales. Eli Lilly's Zepbound and Mounjaro are gaining prescription share. As of July 2025, Zepbound holds 59% of prescriptions compared to Wegovy's 40%, signaling a material shift in market preference. Tired of too many ads? Remove Ads Leadership Transition Amid Turbulence Legal and Regulatory Headwinds Analysts Split: Crash or Correction? Novo Nordisk: Denmark's global pharma giant Tired of too many ads? Remove Ads Key Innovative Advances Bolster Long-Term Outlook Amycretin – Dual-Action Obesity Drug: Phase 1b/2a trials show 22% average body weight loss over 36 weeks, sparking a ~12% stock bump. CagriSema – Record Weight Loss in Phase III: Achieved 20.4% weight reduction in obese adults and 13.7% in type 2 diabetes patients. Oral Semaglutide & Amycretin: Oral formulations are under U.S. regulatory review, potentially broadening adoption. $2.2B Septerna Partnership: Four programs targeting obesity, type 2 diabetes, and cardiometabolic diseases. Insulin Icodec (Awiqli) – Once-Weekly Insulin: Approved in Canada, EU, and Japan, improving patient adherence. NNC2215 – Glucose-Sensitive 'Smart' Insulin: Adjusts activity based on blood sugar, reducing hypoglycemia risk. Alhemo (Concizumab) – Hemophilia Treatment: FDA-approved July 2025 for A and B types. AI and Rare Disease Expansion: Collaborations with Heartseed, Ventus Therapeutics, and megaTAL platform targeting cardiovascular, MASH, and CKD therapies. So, Is This a 'Nokia Moment'? Summary Snapshot Indicator Status Sales & Profit Guidance Significantly lowered; investor reaction strongly negative Competition & Market Threats Rising; compounded drugs and Eli Lilly products erode share Leadership & Strategy New CEO; strategic clarity still evolving Legal & Regulatory Risks Class-action lawsuit; compounding disputes add uncertainty Valuation & Sentiment Deeply discounted; mix of caution and opportunistic value Long-term Outlook Not terminal; pipeline and global expansion offer growth levers Investor Takeaways Defensive stance: Exercise caution until guidance execution and competitive dynamics are clearer. Exercise caution until guidance execution and competitive dynamics are clearer. Value opportunity: Contrarian investors may view the sharp dip as a long-term buying chance, particularly if Novo can regain share and deliver on pipeline milestones. Contrarian investors may view the sharp dip as a long-term buying chance, particularly if Novo can regain share and deliver on pipeline milestones. Catalysts to watch: CEO performance, legal outcomes, regulatory action on compounding, and international R&D breakthroughs. FAQs: Novo Nordisk (NYSE: NVO) closed at $50.39 on Thursday, down $0.51 (-1%), extending its staggering decline from a year-high of $139.74. Investors are questioning whether the Danish pharmaceutical giant is approaching its own 'Nokia moment'—a pivotal inflection point where market dominance is challenged by nimble competitors and shifting industry Novo Nordisk lowered itsfrom. Operating profit (EBIT) growth was also trimmed to. The announcement triggered a, wiping out roughlyInvestors had expected continued dominance in the lucrative obesity and diabetes markets, but the downgrade sent an unmistakable warning: growth is slowing, and the competitive landscape is shifting Nordisk's blockbuster drugsandhave faced growing headwinds:These trends highlight a: traditional competition and unregulated compounding pharmacies undermining pricing CEOstepped down on, passing the reins to. The new CEO faces immediate challenges: stabilizing sales, defending market share, and restoring investor watchers emphasize that leadership changes at such a sensitive moment can either signal a bold strategic pivot or deepen uncertainty, depending on how quickly Doustdar asserts his Nordisk is also navigating U.S. legal scrutiny. A class-action lawsuit claims the company misled investors about competitive risks and overstated growth institutions are taking note: UBS downgraded NVO to 'neutral' and cut its target price from 600 to 340 Danish kroner, warning that competitive and compounding pressures are 'here to stay.'Market opinion is divided. Some analysts foresee additional downside, while others highlight support near $47.50 as a potential stabilization point. Contributors on Seeking Alpha argue that the sell-off may have priced in worst-case scenarios, leaving room for a measured recovery if Novo's R&D pipeline delivers next-generation weight-loss drugs or accelerates global Nordisk started its journey in Denmark in the 1920s, when two small companies—Nordisk and Novo—were founded to make insulin for people with diabetes. In 1989, the two merged to form Novo Nordisk as we know it today. The company's largest owner is the Novo Nordisk Foundation, which holds nearly a third of the shares but controls more than three-quarters of the voting in Bagsværd, just outside Copenhagen, Novo Nordisk has grown into one of the world's most valuable pharmaceutical companies. In mid-2025, it's worth around, although last year it briefly touched almost, putting it among the most valuable companies on the home, its impact is hard to overstate. Novo Nordisk is Denmark's biggest taxpayer, a major exporter, and an economic powerhouse—at one point its market value was larger than Denmark's entire GDP. Today, it's not just a national success story but a global leader in diabetes, obesity, and rare disease short-term headwinds, Novo Nordisk is pursuing multiple growth avenues:These developments suggest Novo's, providing potential long-term exactly. While Novo Nordisk faces heightened competition, slowing growth, leadership changes, and legal pressures, it retains robust cash flows, a dominant market footprint, and a promising turbulence is clear. Yet a full-scale Nokia-style collapse is unlikely given Novo's strategic assets and global reach. The company is navigating a near-term storm, but its innovation engine and expansion efforts leave the door open for Nordisk is at a critical crossroads. The company isn't collapsing, but it's clear that the weight-loss and diabetes markets are no longer uncontested territory. How the company navigates competition, regulation, and innovation in the coming months will determine whether this is a temporary stumble—or the start of a deeper stock fell after 2025 sales guidance cuts and rising competition from Eli Lilly drugs and compounded drugs and pharmacy compounding have reduced market share and investor confidence.
